Radius is a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative endocrine therapeutics in the areas of osteoporosis and oncology. Radius' lead product, TYMLOSÂŽ (abaloparatide) injection was approved by the U.S. Food and Drug Administration for the treatment of postmenopausal women with osteoporosis at high risk for fracture. The Radius clinical pipeline includes investigational abaloparatide injection for potential use in the treatment of men with osteoporosis; an investigational abaloparatide patch for potential use in osteoporosis; the investigational drug elacestrant (RAD1901) for potential use in hormone-receptor positive breast cancer; and the investigational drug RAD140 under investigation for potential use in hormone-receptor positive breast cancer. Source
No articles found.
R1 is a leading provider of revenue cycle services and physician advisory services...
R1 is a leading provider of revenue cycle servi...
Orgenesis is a vertically-integrated biopharmaceutical company with unique experti...
Orgenesis is a vertically-integrated biopharmac...
Magenta Therapeutics is a clinical-stage biotechnology company developing therapeu...
Magenta Therapeutics is a clinical-stage biotec...
Hoth Therapeutics is a development stage biopharmaceutical company focused on prop...
Hoth Therapeutics is a development stage biopha...
Dynavax Technologies Corporation (Nasdaq: DVAX) is a clinical-stage biopharmaceuti...
Dynavax Technologies Corporation (Nasdaq: DVAX)...
ASLAN Pharmaceuticals is a clinical-stage oncology-focused biotechnology company d...
ASLAN Pharmaceuticals is a clinical-stage oncol...
We are Anchiano Therapeutics, a pivotal-stage biopharmaceutical company focused on...
We are Anchiano Therapeutics, a pivotal-stage b...
Join the National Investor Network and get the latest information with your interests in mind.